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ABSTRACT
Objective: To develop evidence-based recommendations
for the management of fibromyalgia syndrome.
Methods: A multidisciplinary task force was formed
representing 11 European countries. The design of the
study, including search strategy, participants, interven-
tions, outcome measures, data collection and analytical
method, was defined at the outset. A systematic review
was undertaken with the keywords ‘‘fibromyalgia’’,
‘‘treatment or management’’ and ‘‘trial’’. Studies were
excluded if they did not utilise the American College of
Rheumatology classification criteria, were not clinical
trials, or included patients with chronic fatigue syndrome
or myalgic encephalomyelitis. Primary outcome measures
were change in pain assessed by visual analogue scale
and fibromyalgia impact questionnaire. The quality of the
studies was categorised based on randomisation, blinding
and allocation concealment. Only the highest quality
studies were used to base recommendations on. When
there was insufficient evidence from the literature, a
Delphi process was used to provide basis for recom-
mendation.
Results: 146 studies were eligible for the review. 39
pharmacological intervention studies and 59 non-phar-
macological were included in the final recommendation
summary tables once those of a lower quality or with
insufficient data were separated. The categories of
treatment identified were antidepressants, analgesics,
and ‘‘other pharmacological’’ and exercise, cognitive
behavioural therapy, education, dietary interventions and
‘‘other non-pharmacological’’. In many studies sample size
was small and the quality of the study was insufficient for
strong recommendations to be made.
Conclusions: Nine recommendations for the manage-
ment of fibromyalgia syndrome were developed using a
systematic review and expert consensus.
Fibromyalgia syndrome (FMS) is a common
rheumatological condition characterised by chronic
widespread pain and reduced pain threshold, with
hyperalgesia and allodynia. Associated features
include fatigue, depression, anxiety, sleep distur-
bance, headache, migraine, variable bowel habits,
diffuse abdominal pain and urinary frequency.1 2
Although the precise pathogenesis remains
unknown, peripheral and central hyperexcitability
at spinal or brainstem level,3–5 altered pain percep-
tion6 and somatisation7 8 have been hypothesised
and demonstrated in some patients.
The American College of Rheumatology (ACR)
classification criteria for FMS9 are the most
commonly used in clinical and therapeutic research.
The healthcare utilisation by patients with FMS is
high averaging over $2000 per patient per year,10 but
it has been shown that positive diagnosis and
management can reduce healthcare utilisation.11
Although effective treatments are available12–14 no
guidelines exist for the management of FMS. The
objectives were to ascertain the strength of the
research evidence on the effectiveness of treatment of
FMS and develop recommendations for its manage-
ment based on the best available evidence and expert
opinion to inform healthcare professionals.
METHODS
Participants
A multidisciplinary taskforce was formed consist-
ing of 19 experts in FMS representing 11 European
countries.
Search strategy
A systematic search of Medline, PubMed, EmBASE,
PsycINFO, CINAHL, Web of Sciences, Science
Citation Indices, Cochrane Central Register of
Controlled Trials and Cochrane Database of
Systematic Reviews using the keywords: ‘‘fibro-
myalgia’’, ‘‘treatment or management’’ and ‘‘trial’’
for all publications till the end of December 2005
was carried out. A manual search of the biblio-
graphies of trials was undertaken to verify that all
published trials were identified.
Inclusion criteria
Included studies had to be clinical trials using the
ACR 1990 classification criteria for FMS9 to select
patients. Studies, including patients with chronic
fatigue syndrome or myalgic encephalomyelitis,
were excluded unless they were divided into
separate comparator groups for analysis.
Assessment of literature
A ‘‘checklist’’ method15 was used to assess quality of
each study. Data were tabulated using a customised
data extraction form. This included number of
patients in each arm, randomisation and blinding
status. Previous reviews have identified two main
outcome measures: pain assessed by the visual
analogue scale (VAS) and function assessed by the
fibromyalgia impact questionnaire (FIQ).16 17 The
main measure of effect was the between-group
difference calculated from the mean change between
the pre- and post-treatment values in these outcome
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measures. Where possible, effect size for the ‘‘best’’ treatments in
each category was calculated (averaged if there was more than one
trial). Rosnow and Rosenthal’s modified version of the Cohen’s d
calculation was used.18 The thresholds used for interpretation
were: values .0.2 = small, .0.5 = medium and .0.8 = large. The
number needed to harm (NNH) was also calculated if possible,
using withdrawal due to adverse event as the event. Additional
information included: recruitment population; duration of disease,
treatment and assessment; number of tender points; and myalgic
score. Other outcome measures considered were also tabulated. If
required data were recorded, but not presented, or not presented in
a suitable format, the author was contacted wherever possible. If
data were only provided in graphical format, this was extracted
where possible. Data extraction was verified by a second
committee member to ensure accuracy. Any discrepancies were
re-evaluated.
Categorising evidence
Owing to the large variability in outcome measures and
assessments data could not be pooled to perform a formal
meta-analysis; therefore studies were classified according to
their randomisation and blinding level. The highest quality
study (randomised controlled trial) for each treatment class was
used as a basis for the recommendations. The ranking was
graded as (with 1 being highest):
1. Randomised controlled double-blind trials
2. Randomised, blinded crossover trials
3. Randomised single blind trials
4. Randomised open trials/non-randomised single blind
5. Non-randomised open trials.
Evidence for each recommendation was categorised according
to study design and strength of each recommendation was
classified according to the criteria previously published.19
The recommendations were discussed at a final committee
meeting and via email for a consensus to be reached. Delphi
exercise was used to base recommendations on when limited
evidence was found by systematic review. Agreement on the
included recommendations was unanimous.
Publication bias analysis
Abstracts published between 2002 and 2005 inclusive in Annals
of the Rheumatic Diseases, Pain, Arthritis & Rheumatism and
Journal of Musculoskeletal Pain were reviewed to guard against
non-inclusion of any negative studies that had not been fully
published. If available, data were extracted. Any contradictory
data would be included when forming the recommendations.
Future research plan
The committee proposed that these recommendations should be
reviewed and updated in 4 years time, to see if (a) quality of trials
and reporting in FMS had improved, and (b) if there was new
evidence to suggest recommendation of new treatments, or to
alter the recommendations of treatments already included.
RESULTS
Research evidence identified
In the preliminary search, 508 studies were identified. Tables 1
and 2 demonstrate how these were short-listed.
Sensitivity analysis
Effect size and NNH for the interventions recommended were
calculated where possible (table 3).
EULAR recommendations
From tables 1–3 the following recommendations were made
(table 4).
Assessment of recommendations
There was no weighting in terms of order of the recommenda-
tions. ! denotes recommendation derived from expert opinion.
! Full understanding of fibromyalgia requires comprehensive
assessment of pain, function and psychosocial context. Fibromyalgia
should be recognised as a complex and heterogeneous condition where
there is abnormal pain processing and other secondary features.
This is based on expert opinion. It is important to recognise that
FMS is a heterogeneous condition comprising a range of symptoms
and features, effective management must take all of these factors
into account. The nociceptive system also has connections with
the stress regulating, immune and the sleep system in the limbic
brain. It is these links that probably lead to the ‘‘syndrome’’
incorporating numerous symptoms and features.
! Optimal treatment requires a multidisciplinary approach with a
combination of non-pharmacological and pharmacological treatment
modalities tailored according to pain intensity, function, associated
features, such as depression, fatigue and sleep disturbance in
discussion with the patient.
This is a logical progression from the first recommendation. It
represents general practice, but is based solely on expert
opinion. As FMS is polysymptomatic, lacking one treatment
that acts on all symptoms, a multidisciplinary approach tailored
to the needs of the individual is often required. This may need
to include self-management via patient education.47–49 Only two
multidisciplinary trials were short-listed in the summary tables
for further analysis.50 51 Other reviews have supported the use of
multidisciplinary treatment,47 48 but highlighted the lack of
high-quality trials in this area.48 52
Heated pool treatment with or without exercise is effective in
fibromyalgia
Heated pool treatment or balneotherapy was reported to be
effective in improving pain and function. Three of five trials
included exercise in the intervention34 35 38 (two positive for
function and two for pain). Of those without exercise, two
were positive for pain and function.34 36 In the third trial only
the heated pool treatment group improved in pain, but no
comparison was made with the control. Function was not
assessed.37 Drop-out for adverse events was very low. Sample
sizes ranged from medium to large. Three of the studies
restricted the use of medications (not stated in the remaining
two). The fairly high quality of this small number of studies
with positive results has led to this recommendation and there
is agreement with previous reviews.47 48
! Individually tailored exercise programmes, including aerobic
exercise and strength training can be beneficial to some patients with
fibromyalgia.
This is based largely on expert opinion with a combination of
some experimental evidence and previous reports.
For aerobic exercise the majority of trials were open (seven of
11). The best quality were a randomised, assessor blind 12-week
study by Richards and Scott, with large sample size,53 and a
smaller randomised single blind study by Valim et al.42 Valim
et al reported an improvement in VAS pain and FIQ compared
with control. Richards and Scott did not report significant
between-group improvements in either of our chosen outcome
measures although the FIQ score did improve more in the
treatment group, and significant between-group improvements
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were seen at 12 months follow-up. All three strength training
studies were randomised but only one single blind. This had no
significant between-group differences in pain or function,
although both improved in the exercise group only.44
In general the quality of studies among exercise trials was
considerably variable. Blinding and/or control was frequently
inadequate. Those that did show some differences in favour of
exercise used usual activity and care for their controls40 41 (with
the exception of Valim et al who had a stretching control
group42). The majority of exercise studies asked for participants
not to change their medication intake while on the trial.9
Although evidence in the literature was poor, the committee felt
that given the safety and benefit of exercise to general health
exercise should be included as a recommendation. The poor quality
of the trials and our predetermined outcome measures were likely
precluding positive outcomes from being shown. In previous
reviews, exercise has been recommended12 16 17 47 48 with aerobic
exercise gaining the most support. It is likely that different forms
of exercise would suit different subgroups of patients, hence these
programmes should be tailored to the individual.
! Cognitive behavioural therapy may be of benefit to some patients
with fibromyalgia.
This is based on expert opinion. The only two studies identified
for our review with pure cognitive behavioural therapy (CBT)
were of poor quality; neither had a control group, both allowed
patients to remain on their usual medication and only one used
either of our predetermined outcome measures.
This is another area in which the poor quality of trials has
masked what experts believe to be a realistic reflection of
possible benefits. While previous review work has also been
hampered by the inadequacy of research in this field, strong
evidence has been reported for CBT with positive results for
pain and function.47
! Other therapies such as relaxation, rehabilitation, physiotherapy
and psychological support may be used depending on the needs of the
individual patient.
This is based on expert opinion and some experimental
evidence. Two studies of moderate quality were identified for
physiotherapy. An open study54 for connective tissue massage,
which had larger subject numbers (25 control and 23 treated)
and lasted 10 weeks, reported improvement in both pain and
function compared with control. Other relaxation and rehabi-
litation techniques are recommended due to expert opinion.
Clinical trial evidence is lacking in these areas, although reviews
report some benefits.47
Tramadol is recommended for the management of pain in
fibromyalgia
Simple analgesics such as paracetamol and other weak opioids
can also be considered in the treatment of fibromyalgia.
Corticosteroids and strong opioids are not recommended.
Table 1 Study breakdown from initial literature search
No. rejected Reason Total
Total identified 508
171 Not relevant 337
72 Reviews 265
29 Not American College of Rheumatology criteria 236
20 Not clinical trials 216
19 Abstracts 197
8 No pain or function assessments 189
5 Follow-up data only 184
4 Fibromyalgia syndrome combined for analysis 180
Eligible clinical trials
19 Data recorded, but not given 161
4 Non-English language: translations reveal to be
ineligible
157
12 Non-English language: translations not available 145
+1 Identified from bibliographies 146
The 146 eligible clinical trials included 59 pharmacological and 87 non-
pharmacological (including multidisciplinary). Studies were further subdivided into
treatment interventions and the highest quality studies from each intervention were
selected to be the basis for recommendations (table 2).
Table 2 Breakdown of the short-listed studies to base
recommendations on, and those eliminated from further analysis
Intervention
Total
no.
No.
omitted
No.
included
Quality of
studies
included
Reasons for
excluding
Analgesics
Systemic 6 3 3 2 = 1, 1 = 2
(crossover)
1 = too few
subjects,
2 = no control
Topical 3 1 2 Both = 1 No control+
combined FMS
and MFP
Antidepressants
Tricyclic
antidepressants
8 2 6 4 = 1, 2 = 2
(crossover)
Single blind
Selective serotonin
reuptake inhibitors
5 1 4 3 = 1, 1 = 2
(crossover)
No control
Dual reuptake
inhibitors
5 2 3 All = 1 No control
5HT2/3 Antagonists 10 6 4 3 = 1, 1 = 2
(crossover)
No control
Monoamine oxidase
inhibitors
4 2 2 Both = 1 1 = data
not clear,
1 = quasi
randomised,
single blind
Others
Triiodothyronine 3 0 3
Individuals 16 4 12 5 = 1, 4 = 2,
3 = 5
No results
Exercise
Pool-based 2 0 2 1 = 3, 1 = 4 –
Aerobic 11 1 10 4 = 3, 6 = 4 No results
Strength 4 1 3 1 = 3, 2 = 4 Open, not
randomised
Mixed 4 3 1 4 2 = open not
randomised,
1 = no data
Education/CBT
Education 2 0 2 4 –
Education+exercise 8 1 7 1 = 3, 7 = 4 No control
CBT 2 0 2 5 –
CBT+exercise 5 2 3 1 = 3, 2 = 4 Open, not
randomised
Combination 8 8 0 Low quality
and limited
data
Dietary 7 3 4 1 = 1, 1 = 4,
2 = 5
No data
Others
Physiotherapy 4 2 2 1 = 3, 1 = 4 No data and no
control
Balneotherapy 4 0 4 All = 4 –
Laser/light 2 0 2 Both = 3 –
Acupuncture 4 1 3 1 = 1, 1 = 3,
1 = 4
No data
Magnets 2 0 2 Both = 1 –
Homeopathy 3 3 0 – No data
Individuals 14 3 11 2 = 1, 1 = 3,
3 = 4, 3 = 5
No data
CBT, cognitive behavioural therapy; FMS, fibromyalgia syndrome; MFP myofascial pain.
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Regarding tramadol, two randomised controlled trials were
identified as eligible for the review.30 31 One was a high-quality
study of large sample size and 13 weeks duration.31 The second
was preceded by an open label study and only included
responders.30 Bennett et al reported positive effects for pain
and function, and Russell et al reported improved pain levels but
no change in function. There was no difference between placebo
and treated group for adverse event withdrawals (high but non-
serious). Bennett et al restricted concomitant medications, but
Russell et al disallowed sedative hypnotics only. Tramadol
should be used with some caution due to the possibility of
typical opiate withdrawal symptoms with discontinuation and
the risk of abuse and dependence.55
The recommendation for simple analgesics and other weak
opioids is based mainly on expert opinion due to insufficient data.56
The negative recommendation for use of strong opioids and
corticosteroids is based on expert opinion. These medications have
significant long-term side-effects and no clinical trials were iden-
tified in FMS. Previous reviews support our recommendation.47 57
Antidepressants: amitriptyline, fluoxetine, duloxetine, milnacipran,
moclobemide and pirlindole, reduce pain and often improve function
therefore they should be considered for the treatment of fibromyalgia
Four of five trials of amitriptyline that assessed VAS pain had
positive outcomes. Only two used the FIQ, one positive. However,
it is important to note, that as highlighted in previous reviews,14
the only trial that lasted longer than 12 weeks did not show a
significant improvement in pain compared with control.58 Two
trials assessing fluoxetine reported positive outcomes for both pain
and function.22 28 These trials were of moderate to high quality,
reasonable samples sizes and 6 and 12 weeks duration. Duloxetine
improved function in two trials and pain in one.25 27 The
milnacipran trial reported an improvement in pain.26 These were
all large, high-quality trials of 12 weeks duration. Moclobemid and
pirlindole were assessed in one trial each, both of high quality and
with improvements in pain.21 23 FIQ was not assessed in either
trial. For all the trials withdrawals due to adverse events were
generally low and non-serious.
In general these trials excluded other medications prescribed
for FMS, with the exception of paracetamol. The only exception
was the Arnold et al trial that also allowed NSAIDs.28 Previous
reviews have agreed with the recommendation of antidepres-
sants with the strongest evidence for amitriptyline (or tricyclic
antidepressants).12 14 47 57
Tropisetron, pramipexole and pregabalin reduce pain and should be
considered for the treatment of fibromyalgia
Two tropisetron clinical trials were eligible. One had positive
results for pain at a dose of 5 mg.59 Spa¨th et al did not report
significantly positive results, but sample size was small and
there was a positive trend in the treated group.32 FIQ was only
assessed in the trial by Spa¨th et al with negative results;
therefore, no firm comment can be made on this outcome
Table 3 Effect size calculated using modified Cohen’s d method for recommended treatments where data
available
Intervention
Effect size (95% confidence interval)
NNHPain Function
Pharmacological
Amitriptyline 1.033 (20.393, 2.458)20–23 0.51 (212.847, 13.868)22 24 45.56 (236.06, 127.17)
Dual re-uptake 0.341 (20.644, 1.323)25 26 0.438 (22.77, 3.647)25 27 9.91 (6.87, 12.96)
MAOI 0.822 (20.024, 1.669)22 23 Cannot calculate 24.29 (2.93, 37.14)
SSRI 0.824 (20.417, 2.064)22 28 29 0.536 (27.323, 8.395)22 28 29 8.25 (5.8, 10.7)
Tramadol 0.657 (20.276, 1.589)30 31 0.189 (26.312, 6.689)30 31 35 (only one study)
Tropisetron 0.799 (20.884, 2.482)32 Cannot calculate 27.47 (only one study)
Pramipexole 0.736 (20.556, 2.028)33 0.606 (27.073, 8.285)33 221 (only one study)
Non-pharmacological
Pool-based exercise 0.437 (20.659, 1.532)34 35 0.495 (21.68, 2.67)34 28 (one study)
Balneotherapy 1.408 (0.684, 2.133)36–38 2.085 (25.334, 9.979)36 38 Cannot calculate
Aerobic exercise 0.377 (20.794, 1.549)39–43 0.062 (25.174, 5.297)39–42 213.5 (one study)
Strength training 2.225 (1.159, 3.292)44 45 1.031 (229.197, 31.259)44 46 16.15 (one study)
MAOI, monoamine oxidase inhibitor; NNH, number needed to harm; SSRI, selective serotonin reuptake inhibitor.
Table 4 EULAR recommendations for the management of fibromyalgia
Recommendation
Level of
evidence Strength
General
Full understanding of fibromyalgia requires comprehensive
assessment of pain, function and psychosocial context.
Fibromyalgia should be recognised as a complex and
heterogeneous condition where there is abnormal pain
processing and other secondary features
IV D
Optimal treatment requires a multidisciplinary approach
with a combination of non-pharmacological and
pharmacological treatment modalities tailored according
to pain intensity, function, associated features such as
depression, fatigue and sleep disturbance in discussion
with the patient
IV D
Non-pharmacological management
Heated pool treatment with or without exercise is effective
in fibromyalgia
IIa B
Individually tailored exercise programmes, including aerobic
exercise and strength training can be beneficial to some
patients with fibromyalgia
IIb C
Cognitive behavioural therapy may be of benefit to some
patients with fibromyalgia
IV D
Other therapies such as relaxation, rehabilitation,
physiotherapy and psychological support may be used
depending on the needs of the individual patient
IIb C
Pharmacological management
Tramadol is recommended for the management of pain in
fibromyalgia
Ib A
Simple analgesics such as paracetamol and other weak
opioids can also be considered in the treatment of
fibromyalgia. Corticosteroids and strong opioids are not
recommended
IV D
Antidepressants: amitriptyline, fluoxetine, duloxetine,
milnacipran, moclobemide and pirlindole, reduce pain and
often improve function, therefore they are recommended
for the treatment of fibromyalgia
Ib A
Tropisetron, pramipexole and pregabalin reduce pain and
are recommended for the treatment of fibromyalgia
Ib A
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measure. Fa¨ber et al made no comment on whether concomitant
medications had been controlled, but Spa¨th et al disallowed
antidepressants, tranquillisers and sedatives. This treatment
appears well tolerated. These were short-term studies, so
further research into longer-term effects is required.
One trial for pramipexole was positive for both pain and
function.33 Frequency of mild/moderate adverse events was high
and this trial did not restrict concomitant medications,
although dosages were kept stable. A monotherapy trial is
required for more conclusive assessment of effect.
One trial reported pregabalin 450 mg reduced pain, but FIQ was
not assessed.60 Drop-outs due to adverse events were largely classed
mild to moderate in severity. All medications for pain and sleep
disorders were restricted, with the exception of paracetamol.
These are recent studies and suggest further research into the
use of these promising medications for FMS. Previous reviews
have also mentioned their potential benefit47 57 (neither include
the pramipexole study as this was not published).
DISCUSSION
These EULAR recommendations are based on expert opinion and
changes in pain assessed by VAS and function assessed by the FIQ
in clinical trials. Positive effects in other outcome measures were
not considered, neither were pain or function if assessed by
different instruments. Consequently some studies were excluded
from our review due to not using these outcome measures, or not
presenting the data. Although other instruments might be more
sensitive in FMS it was decided that setting a standard for outcome
measures was vital so that comparisons could be made fairly
between trials and therefore using those most frequently reported
allowed better analysis.47 61 Previous reviews have used different
inclusion/exclusion criteria and/or assessed more or different
outcome measures producing different evidence.16 47 48
The high variability in outcome measures used, reporting of
results, as well as the inadequacy of methodological quality were
barriers to conducting meta-analysis.12 14 16 17 57 62 This led to
difficulties in producing strict evidence-based recommendations.
In some areas evidence is lacking due to the poor quality of the
studies, where expert opinion suggests otherwise, eg, exercise.
Outcome measures may be decided according to desired
treatment effect. Non-pharmacological interventions have pre-
viously been suggested to have a significantly better effect on
function than medications,62 reflected by its wider assessment in
these studies. However, if this outcome measure is not frequently
assessed in pharmacological trials, results could be biased.
Guidance on how to conduct good randomised controlled
trials in FMS, including standardised outcome measures and
validated, sensitive instruments is important for future research.
For the treatments that were recommended, effect sizes
generally range from medium to high. Although these results
give an indication of the efficacy of each treatment, they should
be interpreted with some caution as they were only calculated
where data were available and could be biased by factors such as
whether or not the outcome measure was assessed. We have not
collected any information on the cost-effectiveness of these
treatments. Further analysis of disease duration and baseline
values does not reveal any obvious pattern that would affect the
outcomes of this review. Review of the abstracts published
between 2002 and 2005 revealed no conflicting evidence to that
derived from the published articles identified.
The assessment of strength of evidence tends to favour
pharmacological studies as double blinding and placebo controls
are impossible in many non-pharmacological studies. However,
most non-pharmacological interventions are safe and have other
health benefits. These important factors were taken into
account in formulating these recommendations.
Summary
These recommendations are the first to be commissioned for
FMS, although previous reviews have addressed the area.47 62
The standard operating procedures published by EULAR63 were
followed. They will be updated every 5 years and it is hoped
that good quality clinical trials in this area will add to the
evidence currently available. These recommendations should
assist healthcare providers, with a secondary intention to
incorporate information into materials for patients.
The nine recommendations included eight management
categories, three of which had strong evidence from the current
literature, and three were based on expert opinion.
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